Table 1.
Radiopharmaceuticals for Radiotheranostics Recently Approved by the FDA
| Name | Target | Classification | Indications | Approved Date |
|---|---|---|---|---|
| [68Ga]Ga-DOTATATE (Netspot) | SSTR2 | Diagnostics | NEN | June 2016 |
| [177Lu]Lu-DOTATATE (Lutathera) | SSTR2 | Therapy | NEN | January 2018 |
| [68Ga]Ga-DOTATOC | SSTR2 > 5 | Diagnostics | NEN | August 2019 |
| [64Cu]Cu-DOTATATE (Detectnet) | SSTR2 | Diagnostics | NEN | September 2020 |
| [68Ga]Ga-PSMA-11 (Locametz) |
PSMA | Diagnostics | Prostate cancer | December 2020 |
| [18F]F-DCFPyL (Pylarify) | PSMA | Diagnostics | Prostate cancer | May 2021 |
| [68Ga]Ga-PSMA-617 | PSMA | Diagnostics | Prostate cancer | March 2022 |
| [177Lu]Lu-PSMA-617 (Pluvicto) | PSMA | Therapy | Prostate cancer | March 2022 |
| [18F]F-rhPSMA-7.3 (Posluma) | PSMA | Diagnostics | Prostate cancer | May 2023 |
SSTR: somatostatin receptor; NEN: neuroendocrine neoplasm; PSMA: prostate-specific membrane antigen.